T-Knife Therapeutics Inc.

https://www.t-knife.com

T-knife is a next-generation T-cell receptor (TCR) company developing a pipeline of therapeutics for solid tumor patients. The company leverages its proprietary humanized T-cell receptor (HuTCR) mouse platform to produce fully human TCRs, naturally selected in vivo for optimal affinity and specificity. T-knife is developing a pipeline of potential first/best-in-class TCR therapeutics against targets with high unmet medical need, including cancer testis antigens, viral antigens and commonly shared neoantigens. T-knife was founded by leading T-cell and immunology experts using technology developed at the Max Delbruck Center for Molecular Medicine together with Charité University Hospital in Berlin. *

	Start	2021-08-02 existent
	Group	T-Knife (Group)
	Industry	TCR engineering technology (T-cell receptor engineering technology)
	Industry 2	HuTCR transgenic mouse platform (T-Knife)

	Region	San Francisco, CA
	Country	United States (USA)
	City	n. a. San Francisco, CA
		Address record changed: 2021-08-02

Basic data	Employees	n. a.

		* Document for »About Section«: T-Knife Therapeutics, Inc.. (8/2/21). "Press Release: T-Knife Therapeutics Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor Therapies". San Francisco, CA & Berlin.

		Record changed: 2024-04-04